Dimensional Fund Advisors LP Buys 126,913 Shares of Repligen Co. (NASDAQ:RGEN)

Dimensional Fund Advisors LP raised its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 28.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 580,485 shares of the biotechnology company's stock after acquiring an additional 126,913 shares during the quarter. Dimensional Fund Advisors LP owned approximately 1.04% of Repligen worth $83,556,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of RGEN. Signaturefd LLC lifted its stake in Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 124 shares during the last quarter. Sava Infond d.o.o. acquired a new stake in shares of Repligen in the fourth quarter valued at approximately $29,000. UMB Bank n.a. boosted its stake in shares of Repligen by 49.1% during the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock worth $48,000 after acquiring an additional 110 shares during the period. Global Retirement Partners LLC increased its holdings in shares of Repligen by 54.0% during the 4th quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock worth $53,000 after acquiring an additional 129 shares during the last quarter. Finally, Pilgrim Partners Asia Pte Ltd bought a new stake in Repligen in the 4th quarter valued at $55,000. Institutional investors own 97.64% of the company's stock.

Analysts Set New Price Targets

RGEN has been the subject of a number of research analyst reports. Canaccord Genuity Group reduced their price objective on shares of Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research report on Wednesday, April 16th. Wolfe Research upgraded shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target on the stock in a research note on Tuesday, April 29th. Royal Bank of Canada cut their price objective on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a research report on Wednesday, April 30th. HC Wainwright reissued a "buy" rating and set a $180.00 price target on shares of Repligen in a report on Monday. Finally, JPMorgan Chase & Co. decreased their price objective on Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a report on Tuesday, April 29th. Six investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Repligen currently has an average rating of "Moderate Buy" and a consensus target price of $173.25.

Insider Buying and Selling at Repligen

In other news, Director Margaret Pax purchased 250 shares of the company's stock in a transaction dated Monday, March 17th. The stock was bought at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the purchase, the director now owns 1,043 shares of the company's stock, valued at approximately $157,169.67. The trade was a 31.53 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.20% of the company's stock.

Repligen Price Performance

Shares of NASDAQ:RGEN traded down $0.41 during midday trading on Monday, hitting $141.10. The stock had a trading volume of 143,159 shares, compared to its average volume of 715,864. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $7.92 billion, a P/E ratio of -277.72, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27. The company's 50-day moving average price is $137.82 and its 200-day moving average price is $145.89. Repligen Co. has a fifty-two week low of $102.97 and a fifty-two week high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating the consensus estimate of $0.35 by $0.04. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The business had revenue of $169.17 million during the quarter, compared to the consensus estimate of $163.65 million. During the same period in the previous year, the business earned $0.28 earnings per share. The company's revenue was up 10.4% on a year-over-year basis. As a group, equities research analysts predict that Repligen Co. will post 1.72 EPS for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.